Why Is Viridian Therapeutics Stock Sinking Monday? - Amgen (NASDAQ:AMGN), Viridian Therapeutics (NASDAQ:V

Amgen scores with new thyroid eye disease formulation

Can Amgen's subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?

Under-the-skin Tepezza comparable to infused version in key study, Amgen says

The findings could help Amgen defend Tepezza’s market-leading position against emerging rivals, though some analysts expressed doubt about its competitive standing.

Why Is Viridian Therapeutics Stock Sinking Monday? - Amgen (NASDAQ:AMGN), Viridian Therapeutics (NASDAQ:V

Viridian Therapeutics Inc. (NASDAQ:VRDN) shares fell sharply Monday following topline Phase 3 data from Amgen Inc. (NASDAQ:AMGN) for TEPEZZA in thyroid eye disease (TED), intensifying competitive pressure in the space. Amgen Data Raises Competitive Pressure The Phase 3 TEPEZZA OBI trial met its primary endpoint, showing a statistically significant 77% proptosis (bulging eyes) response rate among participants during the 24-week placebo-controlled…

Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease

Subcutaneous delivery shows IV‑level efficacy in moderate to severe TED

Amgen reports positive Phase III findings for subcutaneous Tepezza trial

Amgen has reported positive top line results from its Phase III subcutaneous Tepezza trial in adults with moderate-to-severe active TED.The post Amgen reports positive Phase III findings for subcutaneous Tepezza trial appeared first on Clinical Trials Arena.

Amgen's Phase 3 success sets up an eye drug showdown with Viridian

Amgen said that an injectable version of its eye drug Tepezza succeeded in a Phase 3 study for thyroid eye disease, setting up a showdown with the biotech company Viridian Therapeutics which last week also posted Phase 3 results on an injectable treatment.